{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T05:33:08Z","timestamp":1775799188198,"version":"3.50.1"},"reference-count":60,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The accelerated development of the first generation COVID-19 vaccines has saved millions of lives, and potentially more from the long-term sequelae of SARS-CoV-2 infection. The most successful vaccine candidates have used the full-length SARS-CoV-2 spike protein as an immunogen. As expected of RNA viruses, new variants have evolved and quickly replaced the original wild-type SARS-CoV-2, leading to escape from natural infection or vaccine induced immunity provided by the original SARS-CoV-2 spike sequence. Next generation vaccines that confer specific and targeted immunity to broadly neutralising epitopes on the SARS-CoV-2 spike protein against different variants of concern (VOC) offer an advance on current booster shots of previously used vaccines. Here, we present a targeted approach to elicit antibodies that neutralise both the ancestral SARS-CoV-2, and the VOCs, by introducing a specific glycosylation site on a non-neutralising epitope of the RBD. The addition of a specific glycosylation site in the RBD based vaccine candidate focused the immune response towards other broadly neutralising epitopes on the RBD. We further observed enhanced cross-neutralisation and cross-binding using a DNA-MVA CR19 prime-boost regime, thus demonstrating the superiority of the glycan engineered RBD vaccine candidate across two platforms and a promising candidate as a broad variant booster vaccine.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1118523","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T10:33:13Z","timestamp":1677148393000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants"],"prefix":"10.3389","volume":"14","author":[{"given":"George W.","family":"Carnell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Billmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha","family":"Vishwanath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Suau Sans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Wein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte L.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Neckermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne Marie M.","family":"Del Rosario","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander T.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Einhauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest T.","family":"Aguinam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Tonks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angalee","family":"Nadesalingam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Sch\u00fctz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe Qingzhou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minna","family":"Paloniemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Cantoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Peterhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"Asbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Sandig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Temperton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Kinsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan L.","family":"Heeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"B1","unstructured":"Coronavirus disease (COVID-19)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of covid-19 vaccines against the B.1.617.2 (Delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 covid-19 vaccine against the B.1.351 variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"n1088","DOI":"10.1136\/bmj.n1088","article-title":"Effectiveness of the pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: Test negative case-control study","volume":"373","author":"Lopez Bernal","year":"2021","journal-title":"BMJ"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, south Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7038e1","article-title":"Comparative effectiveness of moderna, pfizer-BioNTech, and janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions - united states, march-august 2021","volume":"70","author":"Self","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage b betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat Microbiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: An overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Coronaviruses."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00203-21","article-title":"SARS-CoV-2 spike protein stabilized in the closed state induces potent neutralizing responses","volume":"95","author":"Carnell","year":"2021","journal-title":"J Virol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-020-0478-5","article-title":"A thermostable, closed SARS-CoV-2 spike protein trimer","volume":"27","author":"Xiong","year":"2020","journal-title":"Nat Struct Mol Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00752-2","article-title":"Neutralizing antibodies for the prevention and treatment of COVID-19","volume":"18","author":"Du","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the s protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00910","article-title":"Glycan shielding and modulation of hepatitis c virus neutralizing antibodies","volume":"9","author":"Lavie","year":"2018","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1803990115","article-title":"Structure of the lassa virus glycan shield provides a model for immunological resistance","volume":"115","author":"Watanabe","year":"2018","journal-title":"Proc Natl Acad Sci"},{"key":"B21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1128\/JVI.02608-13","article-title":"Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain","volume":"88","author":"Eggink","year":"2014","journal-title":"J Virol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"13473","DOI":"10.1038\/ncomms13473","article-title":"Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines","volume":"7","author":"Du","year":"2016","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000639","article-title":"Hitting the sweet spot: exploiting HIV-1 glycan shield for induction of broadly neutralizing antibodies","volume":"15","author":"Wagh","year":"2020","journal-title":"Curr Opin HIV AIDS."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm0899","article-title":"Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models","volume":"14","author":"Huang","year":"2022","journal-title":"Sci Transl Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"veab020","DOI":"10.1093\/ve\/veab020","article-title":"The evolutionary dynamics of endemic human coronaviruses","volume":"7","author":"Jo","year":"2021","journal-title":"Virus Evol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12985-021-01633-w","article-title":"Evolutionary trajectory of SARS-CoV-2 and emerging variants","volume":"18","author":"Singh","year":"2021","journal-title":"Virol J"},{"key":"B27","volume-title":"WHO announces simple, easy-to-say labels for SARS-CoV-2 variants of interest and concern","year":""},{"key":"B28","doi-asserted-by":"publisher","first-page":"436013","DOI":"10.1101\/2021.03.18.436013","article-title":"The B1.351 and P.1 variants extend SARS-CoV-2 host range to mice","author":"Montagutelli","year":"2021","journal-title":"bioRxiv"},{"key":"B29","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1038\/s41467-022-34506-z","article-title":"Compensatory epistasis maintains ACE2 affinity in SARS-CoV-2 omicron BA.1","volume":"13","author":"Moulana","year":"2022","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.69091","article-title":"N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2","volume-title":"eLife","author":"Tian","year":"2021"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00756-4","article-title":"S19W, T27W, and N330Y mutations in ACE2 enhance SARS-CoV-2 s-RBD binding toward both wild-type and antibody-resistant viruses and its molecular basis","volume":"6","author":"Ye","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"21254882","DOI":"10.1038\/s41591-021-01413-7","article-title":"Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals","volume":"9","author":"Kustin","year":"2021","journal-title":"Clalit Health Serv."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-021-01696-3","article-title":"Delta coronavirus variant: scientists brace for impact","volume":"595","author":"Callaway","year":"2021","journal-title":"Nature."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1101\/2022.01.14.476382v1","article-title":"Selection analysis identifies unusual clustered mutational changes in omicron lineage BA","author":"Martin","year":"2022","journal-title":"1 that likely impact Spike Funct [Internet]. bioRxiv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04474-x","article-title":"Altered TMPRSS2 usage by SARS-CoV-2 omicron impacts infectivity and fusogenicity","volume":"603","author":"Meng","year":"2022","journal-title":"Nature."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid epidemic expansion of the SARS-CoV-2 omicron variant in southern Africa","volume":"603","author":"Viana","year":"2022","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00688-0","article-title":"New boosters are here! who should receive them and when","volume":"22","author":"Doron","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/bs.aivir.2016.07.001","article-title":"Modified vaccinia virus Ankara: History, value in basic research, and current perspectives for vaccine development","volume":"97","author":"Volz","year":"2017","journal-title":"Adv Virus Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/28.1.235","article-title":"The protein data bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb7269","article-title":"A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV","volume":"368","author":"Yuan","year":"2020","journal-title":"Science."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2349-y","article-title":"Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody","volume":"583","author":"Pinto","year":"2020","journal-title":"Nature."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gki387","article-title":"The FoldX web server: an online force field","volume":"33","author":"Schymkowitz","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.54.070185.003215","article-title":"Assembly of asparagine-linked oligosaccharides","volume":"54","author":"Kornfeld","year":"1985","journal-title":"Annu Rev Biochem"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0997-871","article-title":"Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo","volume":"15","author":"Zufferey","year":"1997","journal-title":"Nat Biotechnol"},{"key":"B46","volume-title":"In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science","author":"Naldini","year":"1996"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1089\/10430340252898984","article-title":"High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter","volume":"13","author":"Demaison","year":"2002","journal-title":"Hum Gene Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.3390\/v13081579","article-title":"Coronavirus pseudotypes for all circulating human coronaviruses for quantification of cross-neutralizing antibody responses","volume":"13","author":"Sampson","year":"2021","journal-title":"Viruses."},{"key":"B49","doi-asserted-by":"publisher","first-page":"e4236","DOI":"10.21769\/BioProtoc.4236","article-title":"Production, titration, neutralisation, storage and lyophilisation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lentiviral pseudotypes","volume":"11","author":"Di Genova","year":"2021","journal-title":"Bio-Protoc."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0035876","article-title":"Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts","volume":"7","author":"Bertram","year":"2012","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50569","article-title":"Isolation and rapid sharing of the 2019 novel coronavirus (SARS-CoV-2) from the first patient diagnosed with COVID-19 in Australia","volume":"212","author":"Caly","year":"2020","journal-title":"Med J Aust"},{"key":"B52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s15010-020-01503-7","article-title":"A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization","volume":"49","author":"Peterhoff","year":"2021","journal-title":"Infection."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/v5010321","article-title":"A genotype of modified vaccinia Ankara (MVA) that facilitates replication in suspension cultures in chemically defined medium","volume":"5","author":"Jordan","year":"2013","journal-title":"Viruses."},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-019-00176-3","article-title":"A deleted deletion site in a new vector strain and exceptional genomic stability of plaque-purified modified vaccinia Ankara (MVA)","volume":"35","author":"Jordan","year":"2020","journal-title":"Virol Sin"},{"key":"B55","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/B978-0-12-420119-4.00001-X","article-title":"TCA precipitation","volume":"541","author":"Koontz","year":"2014","journal-title":"Methods Enzymol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0913-5","article-title":"A serological assay to detect SARS-CoV-2 seroconversion in humans","volume":"26","author":"Amanat","year":"2020","journal-title":"Nat Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc2241","article-title":"A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2","volume":"368","author":"Wu","year":"2020","journal-title":"Science."},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2852-1","article-title":"SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies","volume":"588","author":"Barnes","year":"2020","journal-title":"Nature."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01529-18","article-title":"Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost","volume":"93","author":"Asbach","year":"2019","journal-title":"J Virol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2101076","article-title":"T Cell immunogenicity, gene expression profile, and safety of four heterologous prime-boost combinations of HIV vaccine candidates in healthy volunteers: Results of the randomized multi-arm phase I\/II ANRS VRI01 trial","volume":"208","author":"Richert","year":"2022","journal-title":"J Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1118523\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T15:44:59Z","timestamp":1701963899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1118523\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":60,"alternative-id":["10.3389\/fimmu.2023.1118523"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1118523","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"article-number":"1118523"}}